AJ1-11095
Phase 1Small molecule
AJ1-11095 is one of 33 small molecule programs targeting Essential Thrombocythemia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
44 competitors in Essential Thrombocythemia
#DrugCompanyPhaseTrials
1Droxia
TTheravia
Approved
Jakafi
IncytePhase 3
Trisenox
CCephalon
Approved
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Bayer Aspirin
BayerPhase 3
PEGASYS
Ppharmaand GmbH
Phase 3
Vonjo
OOrsoBio, Inc
Phase 3
Busulfex
Akero TherapeuticsPhase 3
BESREMI
PPharmaEssentia
Phase 3
Bomedemstat
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AJ1-11095. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAjax Therapeutics, Inc.